Citation
Michel, Gérard, et al. "Weight-based Strategy of Dose Administration in Children Using Intravenous Busulfan: Clinical and Pharmacokinetic Results." Pediatric Blood & Cancer, vol. 58, no. 1, 2012, pp. 90-7.
Michel G, Valteau-Couanet D, Gentet JC, et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer. 2012;58(1):90-7.
Michel, G., Valteau-Couanet, D., Gentet, J. C., Esperou, H., Socié, G., Méchinaud, F., Doz, F., Neven, B., Bertrand, Y., Galambrun, C., Demeocq, F., Yakouben, K., Bordigoni, P., Frappaz, D., Nguyen, L., & Vassal, G. (2012). Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatric Blood & Cancer, 58(1), 90-7. https://doi.org/10.1002/pbc.22959
Michel G, et al. Weight-based Strategy of Dose Administration in Children Using Intravenous Busulfan: Clinical and Pharmacokinetic Results. Pediatr Blood Cancer. 2012;58(1):90-7. PubMed PMID: 21254374.
TY - JOUR
T1 - Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
AU - Michel,Gérard,
AU - Valteau-Couanet,Dominique,
AU - Gentet,Jean-Claude,
AU - Esperou,Hélène,
AU - Socié,Gérard,
AU - Méchinaud,Françoise,
AU - Doz,François,
AU - Neven,Bénédicte,
AU - Bertrand,Yves,
AU - Galambrun,Claire,
AU - Demeocq,François,
AU - Yakouben,Karima,
AU - Bordigoni,Pierre,
AU - Frappaz,Didier,
AU - Nguyen,Laurent,
AU - Vassal,Gilles,
Y1 - 2011/01/19/
PY - 2010/07/23/received
PY - 2010/11/11/accepted
PY - 2011/1/22/entrez
PY - 2011/1/22/pubmed
PY - 2012/1/13/medline
SP - 90
EP - 7
JF - Pediatric blood & cancer
JO - Pediatr Blood Cancer
VL - 58
IS - 1
N2 - BACKGROUND: A prospective clinical trial was performed in order to validate the pharmacokinetic (PK) and clinical benefits of a new dosing schedule of intravenous busulfan (IV Bu) in children. PROCEDURE: IV Bu was administered as a 2-hr infusion every 6 hr for 4 days. Five dose levels were given according to body-weight strata. RESULTS: The 67 children aged from 4 months to 17.2 years were followed up over 50 months after autologous or allogeneic stem-cell transplantation. Reduced PK variability was seen after IV Bu administration enabling efficient targeting with 78% of patients within the 900-1,500 µM · min therapeutic window and reproducible exposures across administrations. No neurological complications occurred. The low incidence of hepatic veno-occlusive disease (VOD) recorded was not correlated with high area under the curve (AUC). Only stomatitis was correlated with high AUC in the autologous group. The 4-year overall survival was 59% in the autologous group and 82% in the allogeneic group. CONCLUSION: The new dosing schedule using IV Bu provides adequate therapeutic targeting from the first administration, with low toxicity and good disease control in high-risk children. The choice of this formulation of Bu should be considered because of its low morbidity and good outcome.
SN - 1545-5017
UR - https://www.unboundmedicine.com/medline/citation/21254374/Weight_based_strategy_of_dose_administration_in_children_using_intravenous_busulfan:_clinical_and_pharmacokinetic_results_
L2 - https://doi.org/10.1002/pbc.22959
DB - PRIME
DP - Unbound Medicine
ER -
